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REGRANEX (becaplermin[rhPDGF-BB]) Gel 0.01% is a topical gel used for the 
treatment of chronic lower extremity diabetic neuropathic ulcers (8 weeks or longer). It 
contains growth factors to aid in healing by promoting the formation of granulation tissue. 
Becaplermin[rhPDGF-BB] is the only growth factor to show clinical efficacy and to be 
approved by the FDA. The purpose of this study is to evaluate the effectiveness of this 
topical gel to speed the closing of wounds and/or production of healthy granulation tissue. 
To accomplish this evaluation, a chart review was done at Altru Health Systems. A 
list of names of patients who have been treated at the wound clinic was attained and a chart 
review was done on the basis of this list. Eight patient charts, 4 of which received 
REGRANEX and 4 that did not receive REGRANEX were reviewed. Objective data 
collected from the charts included: length, width and depth of the wound, percent 
granulation tissue, location, cleansing and dressing of the wound. A statistical analysis was 
performed to determine if REGRANEX was an effective wound topical gel. This study 
demonstrated REGRANEX is associated with less eschar and therefore more granulation 
tissue when viewed by the clinician. However, no significant difference was found with 
statistical analysis. Improvement in the formation of granulation tissue is a plus for patients 
with diabetes because it may prevent them from enduring the pain or other side effects that 




REGRANEX (becaplermin) Gel 0.01% was approved by the Food and Drug 
Administration in December 1997 as a treatment for lower extremity diabetic neuropathic 
ulcers. 1 It is a topical gel that contains growth factors to promote the formation of 
granulation tissue. 
A common and serious complication of Diabetes Mellitus is lower extremity 
diabetic ulcers, which can lead to amputations. 1 They are difficult to heal, may last for 
months and often become infected because they remain open. Patients with diabetes have 
decreased immunological systems that make it difficult for the body to fight infections. 
Ulcers result from a variety of etiological factors. 2 Inability to heal is the main 
identifying factor of a chronic ulcer. Minor trauma has been sited as a major contributing 
factor to lower extremity ulcers and can lead to amputations. An example of this is 
trauma related to foot wear. 
Approximately 15% of people diagnosed with diabetes will develop a foot ulcer 
during their lifetime. 1,2,3,4 Each year 2% to 3% of people with diabetes will develop a 
foot ulcer.2 There are approximately 162,000 annual hospitalizations for foot ulcers and 
46% of them have been diagnosed with diabetes. In 1990,2.8 million people with 
diabetes were hospitalized. 1 Approximately 6% of those also had a diagnosis related to 
lower extremity ulcers. Of patients hospitalized with diabetes, the length of stay was 
59% longer if they also had a foot ulcer.2 
1 
If left untreated or treated incorrectly, ulcers may become infected and develop 
gangrene which is the leading cause of amputations in a patient with diabetes. I,3 
Approximately 85% of all nontraumatic lower limb amputations start out as a foot ulcer. 2 
Half of the amputations that are performed in the US are done on people with diabetes. 
In people with diabetes, the annual amputation rate is 15 to 40 times higher than the rate 
in nondiabetic people. 1 Each year approximately 67,000 amputations are performed on 
people with diabetes. I,3,4,s Nearly half of those people will have further amputations of 
the same leg or the opposite leg within 5 years. I,4 Survival rate for individuals with 
diabetes who have had a lower-limb amputation is 50% after the first 3 years and about 
40% after 5 years. 1,3 
Problem Statement 
Social and economic burdens are associated with lower extremity ulcers.3 Some 
of these are loss of income and function and a decline in the patient's quality of life. 
Some economic costs include costs of hospital care, doctor visits, operations, 
rehabilitation, artificial limbs, and long-term care.4 A rapid healing rate can have 
important social and economic advantages for patients and their caregivers.3 
REGRANEX can provide a treatment for these ulcers which can decrease the cost by 
healing ulcers faster. Since REGRANEX is a fairly new product, only a small amount of 
literature has been published about the effectiveness of this topical ointment. This study 
will also provide information about ulcers, healing, REGRANEX and a review of 
previous clinical studies completed on REGRANEX. 
Purpose of the Study 
The purpose of this study is to evaluate the effectiveness ofREGRANEX 
(becaplermin) topical gel to speed the closing of wounds and/or production of healthy 
granulation tissue. A retrospective chart review of patients that received REGRANEX as 
a treatment was performed to accomplish this purpose. 
2 
Significance of the Study 
As Physical Therapists we are involved in the treatment of wounds. The 
significance of this study is to make healthcare employees aware of this type of product 
as another alternative in the treatment of lower extremity diabetic neuropathic ulcers. 
This product may be able to improve patient's lives so they continue as a productive 
citizen. 
Research Questions 
How does this growth factor effect wound healing? 
What is a lower extremity diabetic neuropathic ulcer and how do you treat them? 
What are the stages of wound healing and what is involved in each stage? 
What is REGRANEX? 
How safe and effective has REGRANEX been in previous clinical studies, including 
animal and human studies? 
Hypotheses 
This Independent Study investigates the ability ofREGRANEX to speed the 
closing of wounds and/or increase the production of granulation tissue. Healing is 
defined as a decrease in the amount of percent eschar and area of the wound. Using 
statistical analysis, is there a significant difference in healing between treatment groups 




There are five major factors which contribute to the development and persistence 
of chronic lower extremity ulcers.2,3 They are neuropathy, peripheral vascular disease, 
edema, metabolic factors and infection. When these factors are combined with normal 
mechanical stress during weight bearing, the lower extremity becomes vulnerable to the 
development of ulcers. 3 
Neuropathy 
Most patients with diabetic ulcers on the medial, lateral and plantar surfaces of the 
foot have some degree ofneuropathy.2 Neuropathy effects more than 80% of patients 
with diabetic foot ulcers. 1 Neuropathy is one of the causing factors in 60% oflower 
extremity amputations. 1,4 Slow healing and resistance to traditional treatments are some 
of the characteristics of diabetic neuropathic ulcers.3 Other characteristics include loss of 
motor, sensory and autonomic neural function. 1 
Motor neuropathy will reduce or eliminate nerve signals that are sent to muscle to 
keep proper tension and tone of the muscles.4 Muscle weakness, atrophy and paresis are 
some of the results of motor neuropathy.2 These structural changes make the foot 
vulnerable to injury from wearing shoes which do not fit properly, trauma or repetitive 
stress. 1 Motor neuropathy can also cause foot deformities such as hammer toes, 
Charcot's joint or neuro-osteoarthropathy. The imbalance of muscles can lead to cavus 
or high arched foot. 6 
4 
The clawing of the toes can also cause alterations in the fat pads that protect the 
metatarsal heads. I,6 The muscles and fad pads may be thinner. 1 This makes the plantar 
surface of the foot more susceptible to neuropathic ulcers especially under the metatarsal 
heads. The toes are unable to bear weight when they are severely clawed and the weight 
is then distributed to the metatarsal heads.6 It has been found that 90% of diabetic ulcers 
occur on the foot where pressure from weight bearing is high. 
Sensory neuropathy in a person with diabetes will produce a loss of protective 
sensation. The person then becomes vulnerable to injury from pain, pressure and heat. 2 
Minor trauma may not be felt by the patient and may go unnoticed for a period of time. 
Examples of minor traumas leading to ulceration include foreign objects entering the 
body while barefoot, shoes that do not fit properly, trauma from nail trimming, and burns 
caused by hot water or warming feet on a radiator. 4 When sensation is lost, the person 
may not even realize they have an ulcer.6 The smell, blood stained sock or another 
person's discovery may be the only way the person with diabetes becomes aware they 
have an ulcer. They may also have a loss of proprioceptive sensation? With this loss, 
the person is unable to judge what position their feet are in when they make contact with 
the ground. 
Autonomic neuropathy will alter blood flow in the peripheral vessels and decrease 
perspiration. 1 These conditions along with warm and overly dry feet contribute to skin 
breakdown, such as fissures and cracks.I,2,6 The patient with diabetes has a distinctive 
appearance to their foot with these neuropathic changes.6 This includes a cavus (high 
arched), dry, insensitive foot with dilated veins, good pulses, clawed toes, and 
hyperkeratosis under the forefoot and heel. 
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Peripheral Vascular Disease 
Peripheral Vascular Disease (PVD) or ischemia as the only factor in ulcers is rare 
and occurs in about 10010 to 15% of patients with diabetic foot ulcers.4,6 It is common, 
however, for patients to have some degree of decreased blood supply. About 15% to 
20% have a mix of neuropathy and ischemia. PVD has been a factor in 62% of non-
healing lower extremity diabetic ulcers.2 In 46% of amputations, PVD has been the 
causing factor. PVD is four times higher in patients with diabetes than patients without 
diabetes. 
An early sign ofPVD is claudication which presents as leg pain on walking 
distances? Patients with diabetes may not be able to describe the pain due to 
neuropathy. For this reason they may not realize they have the PVD until tissue loss and 
gangrene occur. Ninety percent of patients with diabetes have surgically correctable 
occlusions. 
Most ulcers due to PVD or ischemia occur in distal parts of the foot (i.e. the 
toes).1 Patients with diabetes, who smoke, have hyperlipidemia, and hypertension are at 
risk for atherosclerosis.4 The most commonly affected vessels are the superficial 
femoral, tibial, and peroneal arteries.6 A single vessel is usually not the only 
involvement.2,6 In a person with diabetes and PVD the usual findings include a bounding 
popliteal pulse and no pulse in the foot. 4 
Peripheral Vascular Disease contributes to limb ulceration, gangrene and it delays 
healing. 1,2 It increases the chances of acquiring an infection and decreases the body's 
ability to fight infection by decreasing the oxygen, nutrients and antibiotics to the area. 
In one study, it was shown that low (less than 30 mm Hg) transcutaneous oxygen tension 
is a risk factor for foot ulcers. 1 
6 
Ulcers can occur with a constant low pressure applied over a length of time in an 
ischemic foot. 6 Shoes and especially new shoes have been shown to cause ulcers due to 
ischemia. People with diabetes are encouraged to wear new shoes for short periods of 
time to prevent ulceration from happening. If an ischemic ulcer is formed, the blood 
supply needed to heal the ulcer is greater then the blood supply needed for the intact skin. 
Edema 
Painful lower extremity edema may be present even in patients with neuropathy. 2 
It delays wound healing by decreasing the cutaneous blood supply. When the patient's 
shoes do not allow for edema, the increased pressure makes their feet vulnerable to minor 
trauma and ulcers. Treatment for edema includes control of infection, foot elevation, 
compression stockings, elastic leg wraps and pneumatic compression devices. 
Metabolic factors 
Hyperglycemia, or high glucose levels, is common in patients with diabetes? The 
effects of hyperglycemia influences the development of complications in diabetic 
patients. These complications usually appear 15 years after hyperglycemia develops. 
With hyperglycemia, sorbitol accumulates on nerves and attributes to neuropathy. 
Another possible metabolic disturbance is in the glycation of proteins including collagen 
and fibrin. Glycated proteins contribute to the microvascular and macrovascular 
derangements of diabetes. This causes problems because an essential part of wound 
healing is the synthesis of proteins such as fibroblasts and collagen. 
Infection 
Some factors that predispose patients to infection include poor granulation tissue 
formation, prolonged persistence of abscesses and impaired wound healing? Abnormal 
leukocyte function develops from high glucose and low oxygen levels, which increases a 
patients risk for developing infections once the skin is broken. 1 The possibility of 
infection is increased in areas where bacteria is high (i.e. the foot) . Some complications 
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of infection that may develop include cellulitis, osteomyelitis and gangrene. S These often 
lead to amputations. 
Once infection has occurred, it can delay wound healing. It has been shown that 
S 
wounds with greater than 10 colonies of bacteria per gram of tissue have a lower healing 
rate than those with fewer bacterial colonies. S Infection prolongs inflammation which 
delays wound healing and contributes to chronic lower extremity diabetic ulcers. I 
The Wound Healing Process 
Normal wound healing happens in an orderly progression. I The injury occurs, 
platelets arrive and release coagulation factors and growth factors. Homeostasis is 
achieved by intense vasoconstriction for 5 to 10 minutes after injury. The wound is 
cleared of dead tissue and foreign material. 7 The wound is then ready for healing and 
regeneration. There are 3 phases involved in normal wound healing: Inflammation, 
Proliferation and Remodeling.l 
The inflammation phase lasts 4 to 6 days after injury. I After the initial 
vasoconstriction, vasodilation occurs to allow capillary permeability.7 During this time 
cells are recruited into the wound in an orderly fashion. I This is regulated by growth 
factors, including platelet-derived growth factor (pDGF), which are released by the 
platelets during coagulation. An influx of cells occur including neutrophils, macrophages 
and fibroblasts. 1,7 Neutrophils are among the first to arrive. I Macrophages job is to kill 
bacteria and ingest debris. There must be adequate tissue oxygen tension for the killing 
of bacteria to occur.7 During the first 3 hours it is important to kill the bacteria to prevent 
colonization. Macrophages are also a significant source of growth factors, such as PDGF 
which playa key role in migration and activation of wound fibroblasts.I ,7 
The proliferative phase begins 4-6 days after injury and lasts approximately 3 
weeks. I Neovascularization occurs with the creation of an extracellular matrix, including 
collagen, in the wound bed and epithelializtion. This phase is regulated by growth factors 
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that are secreted by macrophages and fibroblasts. Fibroblasts produce substances 
essential for wound repair.7 They are the main source of collagen and wound connective 
tissue. With no infection present, there is a continual decrease in the number of 
inflammatory cells. 1 
The remodeling phase begins 3-4 weeks after injury and it may continue for up to 
2 years. 1,7 There is a balance of collagen deposition and degradation. There is a 
reorganization of collagen fibers into a more organized structure. The collagen continues 
to increase in tensile strength to withstand outside forces better than tissue prior to 
remodeling. It eventually reaches a plateau which is only 80% as strong as normal tissue. 
Impediments in Wound Healing 
A chronic wound does not heal in an orderly progression and it has decreased 
structural integrity.I,7 Skin ulcers are the most common chronic wound. Seventy percent 
are due to pressure ulcers, diabetic foot ulcers and venous ulcers. Some factors which 
impede healing include wound hypoxia, infection, presence of debris and necrotic tissue, 
use of anti-inflammatory medications, a diet deficient in vitamins or minerals, or general 
nutritional deficiencies, tumors, environmental factors and metabolic disorders.8 If 
factors that impede wound healing are identified and controlled the wound will heal 
faster. Studies have suggested that growth factors may stimulate healing. Growth factors 
will work more efficiently in an environment free of these factors. 
Wound hypoxia is the lack of oxygen to a wound. If there is only 30 to 40 mm 
Hg of oxygen present, fibroblasts cannot replicate and collagen production is limited.8 
Wound hypoxia also leaves the wound vulnerable to bacteria. Possible causes of hypoxia 
are scar tissue around the vessels which decrease diffusion of oxygen and nutrients. This 
is the case with venous ulcers. Compressive therapy is used to treat this condition. In the 
case of arterial insufficiency, treatment should include bypass grafting to increase the 
amount of oxygen delivered to the area. 
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Infection of a wound may decrease healing by releasing bacterial enzymes that 
lessen the effects of fibrin and growth factors. S,8 All wounds have some bacteria present. 8 
s 
As stated before if there is more than 10 bacteria per gram of tissue present, the wound is 
considered infected. When foreign debris is present in a wound, it does not take as many 
bacteria to cause an infection. Bacteria are able to grow in the dead tissue. Debridement 
is the main way to rid bacteria from the wound. 
The use of anti-inflammatory drugs impedes wound healing. 8 Steroids, an 
example of these, reduce wound healing by delaying inflammation. These effects can be 
reversed by the administration of vitamin A. Nonsteroidal anti-inflammatory drugs also 
impede wound healing. 8 Examples of these are aspirin and ibuprofen. They decrease 
collagen production and the exact mechanism is unknown. Patients may need to change 
pain medication until the wound shows signs of healing. 
Tobacco is another impeding factor. 8 It increases hypoxia or decreases oxygen 
to the wound. This occurs because the blood vessels are vasoconstricted. The patient 
should be encouraged to limit tobacco use, including nicotine patches. Vitamin and 
mineral deficiencies can also playa large role in impeding wound healing. If there is any 
doubt as to the patient's nutritional status, supplements should be given. 
Tumors should be considered as a differential diagnosis when evaluating a 
wound. 8 Chronic skin cancer may result in tumors. A chronic wound is also at risk of 
developing a Marjolin's ulcer which is aggressive squamous cell carcinoma. A tissue 
biopsy should be performed if etiology is in doubt. The use of topical growth factors is 
contraindicated if malignancy is present. 
Some environmental factors which delay wound healing include pressure and 
wound temperature. 8 Pressure must be relieved from the wound for it to heal. Wound 
temperature of less than 30 degrees Celsius reduces the wounds strength after healing. 
This is most likely due to vasoconstriction and decreased perfusion. 
10 
The metabolic disorder diabetes mellitus is one of the most common diseases in 
patient with chronic wounds. 8 It impairs wound healing in all 3 phases. 1 Patients with 
diabetes have a decreased inflammatory response, fibroblast proliferation, and collagen 
accumulation, due to the high glucose concentrations.1,8 This decreases the tensile 
strength of the wound. The healed wound will only be approximately 80% the original 
strength which leaves them vulnerable to reinjury.l 
Poor blood glucose control also impairs leukocyte function which increases 
susceptibility to infection. 1,8 The macrophages' ability to kill bacteria is reduced and 
makes chronic wounds more difficult to heal. 8 Disease management should be 
implemented to prevent and heal ulcers. 1 
Principles of Good Wound Care 
Growth factors, such as rhPDGF, are more effective when combined with good 
wound care. S Good wound care includes first assessing the wound and then determining 
the extent of damage and the cause of the wound.l The most important components of 
good wound care include debridement, infection control, pressure relief and maintaining 
a moist wound bed.1,3 
In one study it was determined that debridement plays a vital role in the care of 
chronic diabetic foot ulcers. S Debridement removes useless and dead tissue, which 
includes callus, necrotic tissue and infected tissue.l This tissue impedes healing and 
increases the risk of infection. Debridement has many advantages. S The examiner is able 
to inspect the wound easier for infection. When removing calluses, excess pressure on 
the wound may be relieved. The examiner can view any other sources of pressure (i.e. 
bony prominences) and relieve the pressure point by removing it. Tissue with 
excessively high bacterial count can be removed to increase healing.5,8 Aging or old 
cells, which may have lost their ability to produce granulation tissue, can be removed 
from the wound, which may stimulate the production and release of growth factors. 
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Debridement also enhances the effects ofREGRANEX by aIlowing it access to viable 
tissue and ceIl receptor sites. 1 
Infection of the wound needs to be controlled due to the fact that it delays healing 
by prolonging the inflammatory phase of wound healing, destroys healthy tissue and 
prohibits new tissue from being deposited. 1 Local infection can be prevented by sharp 
debridement of infected tissue and applying saline moistened gauze dressings. If not 
prevented, infection of the bone may occur which is known as·osteomyelitis.4 The most 
effective way to treat it, is by removing the infected bone. The patient wiIl require 
antibiotics also. 
Non-weight bearing is criticaIly important.4 This should be maintained at all 
times. The use of crutches, a walker, a wheelchair, walking casts, walking splints or 
other devices can help with off-loading. 1,4 If complete off-loading is impossible then try 
to relieve as much as is possible. 1 Off-loading should be continued for the rest of the 
patient's life or the ulcer may reoccur. 
It is important that the environment of the wound stay moist. 8 This prevents 
further tissue damage. 1 Wounds that are exposed to the air wiII have an increafie in tissue 
necrosis and death of ceIIs. 8 If eschar is formed and is not removed, epithelialization wiII 
be impaired. Wet-to-dry dressings may be more harmful than beneficial. The dressing 
may remove the margin where epithelial tissue is forming and therefore impair wound 
healing. A moist environment can be achieved by changing the dressing 2 times per day 
with a saline moistened gauze. 1 
Platelet-derived Growth Factors (pDGF) 
Growth factors were discovered in the late 1970's.9 Platelet-derived growth 
factors (pDGF) were one of the first growth factors to be discovered and they play an 
important role in wound healing. The phases of wound healing are initiated and 
regulated by growth factors which include PDGF. 1 Platelet-derived growth factors are 
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synthesized and released at or near the wound site. A major source ofPDGF are 
platelets. Macrophages are also a major source ofPDGF. Platelet-derived growth factors 
are also produced by endothelial cells and under certain circumstances, fibroblasts. 10 
All the primary healing components either synthesize and release or respond to 
PDGF indicating how they are an integral part of the wound healing process. 1 Some of 
the activities that PDGF is involved in include cell mitogenesis and migration and 
synthesis of protein and extracellular matrix components. lO Cell chemotaxis and 
proliferation of inflammatory cells is stimulated by PDGF. 1,10 Platelet-derived growth 
factors also stimulate macrophages to migrate to the wound site.in later stages of wound 
healing. During the remodeling phase, PDGF plays an important role in synthesizing the 
extracellular matrix such as collagen and stimulating the lysis of collagen. 
PDGF-BB is a homodimer [two identical proteins (B) are formed together] of 
PDGF held together by intermolecular disulfide bonds and is a dimeric protein. 1,3,10 
Becaplermin [rhPDGF-BB], a recombinant human form ofPDGF, is produced by 
inserting the human gene for the B chain ofPDGF into the yeast Saccharomyces 
cerevisiae. It is purified and can than be applied to wounds. 1 
Becaplermin (rhPDGF-BB) gel contains either 30 or 1 OO~g ofbecaplermin per 
gram of vehicle gel, sodium carboxymethyl cellulose aqueous-based gel or NaCMC. 1,3 It 
is commercially known as REGRANEX (becaplermin) Gel 0.01 %. 
REGRANEX (becaplermin) Gel 0.01% 
REGRANEX is the first recombinant human growth factor to be developed and 
approved by the FDA for the treatment of lower extremity diabetic neuropathic ulcers. 1,9 
The active ingredient is becaplermin.l REGRANEX is available in 2, 7.5 or 15 gram 
multi-use tubes. It is a clear, colorless to straw-colored topical gel. 
The REGRANEX gel is indicated for the treatment of lower extremity diabetic 
neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an 
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adequate blood supply.l,9 When it is used along with good wound care, REGRANEX has 
been shown to increase the incidence of complete healing. The efficacy in the treatment 
of other types of chronic, nondiabetic wounds is under investigation. 
Contraindications for REGRANEX are few. Those patients with a known 
hypersensitivity to any component of the gel should not be using this treatment. l It is 
also not to be used with known neoplasms at the site of application. REGRANEX should 
not be used on wounds that close by primary intention (surgical incisions). The reason is 
that REGRANEX is a nonsterile, low bioburden, preserved product. 
REGRANEX has an excellent safety profile. l Although.safety and effectiveness 
have not been established in patients below 16 years of age. In a study in mice, toxicity 
was not observed at a significant level following a single IV dose of3 mg/kg 
becaplermin.11 In another study, systemic toxicity was not evident in rabbits or monkeys 
following multiple doses ofbecaplermin. The rabbits also did not show significant 
dermal irritation. No cardiographic abnormalities were seen in monkeys following high 
doses ofbecaplermin. 
In a bacteria and mammalian cell mutation assay results indicated that 
becaplermin was not mutagenic.11 Becaplermin did not induce unscheduled DNA 
synthesis and it is not considered a reproductive genotoxin or a systemic carcinogen. The 
study concluded that based on the results, the potential for becaplermin to cause adverse 
reactions after being applied to open wounds is insignificant. 
Similar incidence of adverse reactions such as infection, cellulitis and 
osteomyelitis occurred in patients receiving REGRANEX, placebo gel and good wound 
care alone. 1 Erythematous rashes occurred in 2% of patients treated with REGRANEX 
gel or placebo gel and none in patients receiving good wound care alone. Patients who 
were treated with REGRANEX did not develop antibodies against becaplermin. 
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It is not known ifREGRANEX can cause fetal harm or be excreted in milk so 
caution should be used when administering in these situations. 1 It is also not known if 
REGRANEX interacts with other topical medications that have been applied to the ulcer 
site. This has not been studied. 
Preclinical Animal Studies 
Animal studies have shown that rhPDGF-BB accelerates the wound healing 
process by promoting the formation of granulation tissue. 1.9.10 Within these studies 
epithelialization, contraction, granulation tissue formation, and wound strength were 
evaluated.9 
In a guinea pig partial-thickness model it was found that becaplermin had no 
consistent effect on epithelialization and contraction and these parameters were thrown 
out of later studies.9 However, becaplermin was found to be effective in increasing the 
granulation tissue thickness of the wound bed by at least 2- to 3-fold over vehicle control 
in this model. The efficacy ofbecaplermin was reduced in shallow wounds with many 
hair follicles that epithelialize quickly suggesting that the effects diminishes as the 
wounds remodel. 
In the pig full-thickness model effects ofbecaplermin on granulation tissue was 
evident and statistically significant at day 7, but diminishes by day 14, when 
epithelializtion was nearly complete.9 The conclusion of this study was that PDGF has 
been repeatedly shown to enhance the formation of granulation tissue in animal studies 
but its effects on epithelialization and wound contraction has been variable. Becaplermin 
was developed on the assumption that by stimulating a rich vascular wound bed it would 
promote epithelial ingrowth. One must take into consideration that no animal study will 
completely mimic a chronic human wound. 
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Dosage and Administration 
The amount ofREGRANEX that should be applied to a wound depends on the 
size of the ulcer.1 The first step in deciding the dosage is measuring the greatest length 
and the greatest width. These two numbers are then multiplied. If they were measured in 
inches then that number is multiplied by 0.06 and if it is measured in centimeters, it is 
divided by 4. In other words, each square inch of ulcer surface requires approximately 
2/3 inch length ofREGRANEX gel from a 15 gram tube. Each square centimeter of 
ulcer requires 0.25 cm length ofREGRANEX gel from a 15 gram tube. 
Once the dose is determined REGRANEX gel should be. squeezed from the tube 
onto a clean measuring surface i.e. wax paper. 1 The gel can then be applied with a 
tongue blade or cotton swab over the ulcer in a thin, continuous layer approximately 1116 
inch thick. It is then covered with saline moistened gauze dressing and left for 12 hours. 
After that time it is rinsed with saline or water to remove excess gel. The ulcer is then 
covered with a saline moistened gauze without application ofREGRANEX. 
REGRANEX is to be applied one time per day and excess application has not been 
proven to be beneficial. The amount ofREGRANEX to be applied should be 
recalculated weekly or biweekly. Use ofREGRANEX should be reassessed if the ulcer 
does not show a decrease in size by 30% after 10 weeks of application or complete 
healing after 20 weeks. REGRANEX must be stored in the refrigerator. 
Clinical Efficacy 
Four randomized controlled studies were completed on REGRANEX. There 
were 922 patients which participated in the studies. 1 The first study was completed on 
118 patients with diabetic neurotrophic foot ulcers.5 They were treated with either 
REGRANEX Gel 0.003% or a placebo gel. 1 The criteria for the study included all 
patients free of infection, all ulcers were secondary to neuropathy, had adequate arterial 
blood supply and wounds were present for at least 8 weeks. 5 Patients were excluded if 
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they had poor diabetes control, renal failure, abnormal liver function and no patients with 
exposed bone were included in this study. Patients were treated until the ulcer was 
completely healed or up to 20 weeks. Healing was defined as 100% closure. 
All the patients had aggressive, sharp debridement of callus and necrotic tissue 
down to bleeding tissue initially and then as needed throughout the study.5 The mean 
percentage of office visits where debridement was performed was 46.8% for 
REGRANEX and 48.0% for the placebo gel. The results of this study included 48% of 
patients treated with REGRANEX healed and 25% of patients treated with the placebo 
gel healed during the 20 weeks. For the REGRANEX group, the site with the highest 
debridement rate had the highest healing rate and the site with the lowest debridement 
rate had the lowest healing rate. For the placebo group, the site with the lowest 
debridement rate had the lowest healing rate but at the sites with higher debridement 
there was no relationship between healing and frequency of debridement. 
In a second study 382 patients were treated with either REGRANEX gel 0.01%, 
REGRANEX gel 0.003% or a placebo gel.3 The incidence of complete healing for the 
REGRANEX 0.01% group was 50%, REGRANEX 0.003% group was 36% and the 
.placebo group was 35%. Treatment with REGRANEX 0.01% increased the incidence of 
complete healing by 43% when compared with the placebo group. The study found that 
there was no statistically significant difference in the incidence of complete healing 
between patients receiving REGRANEX 0.003% and the placebo group. 
There were 3 groups with 172 patients in the third study.12 The groups were good 
wound care alone, good wound care plus NaCMC (Sodium Carboxymethyl cellulose) gel 
and good wound care plus becaplermin gel 1 00 ~g/g, NaCMC is the vehicle gel. It was 
found that the incidence of complete healing for the good wound care alone was 22%, 
NaCMC group was 36%, and becaplermin group was 44%. 
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The fourth study included 250 patients. 1 The 2 groups in this study were 
REGRANEX gel and good wound care alone. The incidence of complete healing for the 
REGRANEX group was 36% and for good wound care alone was 32%. These were not 
statistically different in this study. 
There was a 3 month follow-up study completed for the incidence of ulcer 
recurrence. l It was found that 30% of patients had an incidence of ulcer recurrence. This 




A review of medical charts was completed at AItru Wound Clinic to determine if 
REGRANEX is effective in speeding the closing of wounds and/or production of healthy 
granulation tissue. AItru Wound Clinic was contacted for permission to review charts on 
adult patients (18 years or older) who had been treated for lower extremity ulcers. 
Subjects 
Medical charts selected included patients who had received REGRANEX as a 
treatment for lower extremity ulcer(s) and patients who did not receive REGRANEX as a 
treatment but had a similar medical background. A description of demographic data on 
subjects included in this study is summarized in Table 1. 
Subjects were assigned to 2 separate groups on the basis of treatment. The 
treatment group received REGRANEX application 1 time per day while the control group 
did not receive REGRANEX. Both groups received normal clean wound care. 
Information on the treatment they received was located in their medical charts. 
Approval and Consent forms 
Approval was obtained prior to any coIIection of data. This was accomplished 
by completing a University of North Dakota (UND) Human Subject Review Form 
(Appendix A) and submitting it to the UND Institutional Review Board. Approval was 
also obtained from AItru Health Systems Institutional Review Board. 
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Table 1. Demographic data of patients used in chart review. 
DATE REGRANEX/ 
SEX OF NO PAST MEDICAL 
ID# MIF BmTH REGRANEX HISTORY DIAGNOSIS 
1 F 06/05111 REGRANEX Cellulitis Venous stasis ulcer, 
dermatitis, venous 
insufficiency 
2 M 12/28/26 No Carotid occlusive Diabetes, severe 
REGRANEX disease, AAA, gout, neuropathy, PVD, 
renal insufficiency, coronary disease, 
heart bypass COPD, obesity 
3 F 08/09/42 No CHF, renal Diabetes, chronic 
REGRANEX insufficiency, (B) calcaneal 
carotid artery osteomyelitis, HTN, 
stenosis obesity, asthma, good 
circulation 
4 F 11114/60 No Good arterial Ulcer left foot, 
REGRANEX circulation Diabetes, peripheral 
neuropathy, HTN, 
asthma 
5 F 07/07/24 No Head and neck Diabetes, Neuropathy 
REGRANEX cancer, normal 
circulation, 
claudication 
6 F 06/21/38 REGRANEX Ovarian cancer, Diabetes, severe 
cellulitis neuropathy, Charcot 
foot 
8 F 04/24/37 REGRANEX HTN, orthotic, Neuropathic, chronic 
normal arteriole and recurrent left heel 
circulation ulcer 
9 M 08/03/27 REGRANEX Smoker, HTN Diabetes, neuropathy, 





A data collection tool (Appendix B) was used to gather demographic data, 
location of wound, treatment procedure, length, width, depth and percent granulation and 
other information about the patient and their wounds. 
Procedure 
Upon completion of the approval process, a list of names was compiled by the 
Altru Wound Clinic. This list included subjects who had received REGRANEX and 
subjects who did not receive REGRANEX as a treatment but had similar medical 
backgrounds. Altru Medical Records department was then contacted and given the list of 
names. The chart review took place at the medical records department. 
Data was gathered from the Altru Initial Wound Documentation Record and the 
Altru Wound Care Flowsheet (Appendix C) in the chart using the data collection tool 
(Appendix B) previously described under instrumentation. 
Data Analysis 
The independent variables used in this study included treatment, REGRANEX or 
no REGRANEX, and time (Start, Month 1, Month 2, Month 3). The dependent variable 
used was size of wound (area) and the percentage of eschar. Data collected will be 
analyzed with the Statistical Package for Social Sciences (SPSS) version 8.0 software to 
demonstrate if there is significant improvement in size of ulcer when compared with the 





Eight charts were reviewed at Altru Health Systems, one was eliminated due to 
the type of ulcer and the patient's medical history. A total of 12 wounds were evaluated 
from which data collected included the percentage of eschar and wound size (area = 
length x width). This information was utilized to evaluate the effectiveness of 
REGRANEX (becaplermin) gel 0.01% to speed the closing of wounds and/or production 
of healthy granulation tissue. The length and width of the ulcers were measured in 
centimeters and are recorded in Tables 2 and 4 for patients who were treated with 
REGRANEX. Infonnation for those individuals who did not receive REGRANEX can 
be found in Tables 3 and 5. Percentage of eschar can be found in Tables 6 and 7. Data 
was analyzed on SPSS using a two-way analysis ofvariance.13 
The statistical analysis for percent eschar is as follows: 
• An interaction occurred between treatment and time. F(3,31) = 3.417; P < 0.05; 
P = 0.03 
• Treatment has a significant effect on percent eschar. F(1,31) = 11.371; P < 0.05; 
P = 0.002 
• Time has a significant effect on percent eschar. F(3,31) = 5.810; P < 0.05; P = 0.003 
When looking at time as a simple main effect for percent eschar: 
• There was a significant difference between times for percent eschar with no 
REGRANEX. F(3,31) = 4.829; P < 0.05; P = 0.015. The significant difference was 
between initial evaluation and month 2. 
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Table 2. Length of ulcers at each time interval measured in centimeters in patients 
treated with REGRANEX. 
LOCATION OF 1ST 2ND 3lW 
ID# ULCER INITIAL MONTH MONTH MONTH 
1 Right medial ankle 3.3 3 2.9 2.8 
1 Right lateral ankle 1.5 1.5 1.4 1.3 
6 Right foot plantar- 0.7 0.6 0.2 Healed 
lateral 
6 Right foot plantar- 0.3 0.2 Healed Healed 
middle 
6 Right foot plantar- 3.5 2.7 2.3 2.1 
medial 
8 Left heel 2.4 2.7 2.8 2.8 
9 Left heel 1.2 0.13 0.4 0.2 
Table 3. Length of ulcers at each time interval measured in centimeters in patients not 
treated with REGANEX. 
LOCATION OF IIH 2ND 3lW 
ID# ULCER INITIAL MONTH MONTH MONTH 
2 Right great toe 1 0.6 0.2 * 
2 Left great toe 2.1 1.0 0.8 * 
3 Right heel plantar 3.4 Not * * 
measured 
4 Left great toe-base 0.3 Not 0.3 0.6 
measured 
4 Left great toe-lateral 0.3 0.2 Healed Healed 
5 Right heel-medial 2 2 * * 
5 Right great toe 0.2 0.1 * * 
* These patients did not return to the physician. 
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Table 4. Width of ulcers at each time interval measured in centimeters in patients treated 
with REGRANEX. 
LOCATION OF 1ST 2ND 3IW 
ID# ULCER INITIAL MONTH MONTH MONTH 
1 Right medial ankle 1.3 1.1 1.1 1.2 
1 Right lateral ankle 1.1 1.1 1.1 1.0 
6 Right foot plantar- 1.2 0.7 0.5 Healed 
lateral 
6 Right foot plantar- 0.3 0.2 Healed Healed 
middle 
6 Right foot plantar- 3.4 2.9 1.4 1.4 
medial 
8 Left heel 2.1 2.4 2.5 2.5 
9 Left heel 0.4 0.5 0.4 0.4 
Table 5. Width of ulcers at each time interval measured in centimeters in patients not 
treated with REGRANEX. 
LOCATION OF 1M 2NJJ 3IW 
ID# ULCER INITIAL MONTH MONTH MONTH 
2 Right great toe 0.7 0.4 0.3 * 
2 Left great toe 1.5 1.4 1.1 * 
3 Right heel plantar 3.4 Not * * 
measured 
4 Left great toe-base 4.7 Not 2.5 0.7 
measured 
4 Left great toe-lateral 2.7 0.2 Healed Healed 
5 Right heel-medial 1.0 1.3 * * 
5 Right great toe 0.2 0.1 * * 
* These patients did not return to the physician. 
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Table 6. Measurement of percent (%)eschar and necrotic tissue at each time interval in 
patients treated with REGRANEX. 
LOCATION OF 1ST 2ND 3KD 
ID# ULCER INITIAL MONTH MONTH MONTH 
1 Right medial ankle 20 20 20 20 
1 Right lateral ankle 50 30 30 30 
6 Right foot plantar- 20 0 10 Healed 
lateral 
6 Right foot plantar- Not Not Healed Healed 
middle measured measured 
6 Right foot plantar- 20 0 0 0 
medial 
8 Left heel 0 0 0 0 
9 Left heel 10 0 0 20 
Table 7. Measurement of percent (%) eschar and necrotic tissue at each time interval in 
patients not treated with REGRANEX. 
LOCATION OF 1ST 2ND 3KD 
ID# ULCER INITIAL MONTH MONTH MONTH 
2 Right great toe 50 60 10 * 
2 Left great toe 90 85 30 * 
3 Right heel plantar 60 90 * * 
4 Left great toe-base 20 20 Pale pink Not 
callous measured 
4 Left great toe-lateral Not 10 Callous Healed 
measured Healed 
5 Right heel-medial 80 70 * * 
5 Right great toe 100 10 * * 
* These patients did not return to the physician. 
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• There was no significant difference between times for percent eschar with 
REGRANEX. F(3,31) = 2.554; P < 0.05; P = 0.097 
When looking at treatment as a simple main effect for percent eschar: 
• There was a significant difference in percent eschar at initial evaluation between 
treatment groups. F(1,31) = 12.224; P < 0.05; P = 0.008 
• There was a significant difference in percent eschar at month 1 between treatment 
groups. F(1,31) = 5.136; P < 0.05; P = 0.050 
• There was no significant difference in percent eschar at month 2 between treatment 
groups. F(1,31) = 1.464; P < 0.05; P = 0.266 
• There was no significant difference in percent eschar at month 3 between treatment 
groups. F(1,31) = 0.357; P < 0.05; P = 0.576 
The statistical analysis for size (area in centimeters) is as follows: 
• No interaction occurred between treatment and time. F(3,30) = 0.068; P < 0.05; 
P = 0.976 
• Treatment had no significant effect on size. F(1,30) = 1.952; P < 0.05; P = 0.173 
• Time had no significant effect on size. F(3,30) = 0.813; P < 0.05; P = 0.497 
When looking at main effects only without a two way interaction: 
• There was no significant difference in size (area in centimeter) between treatments. 
F(1,30) = 2.126; P < 0.05; P = 0.154 
• There was no significant difference in size (area in centimeter) between time. 
F(3,30) = 0.942; P < 0.05; p = 0.431 
When looking at time as a simple main effect: 
• There was no significant difference for size (area in centimeter) with no 
REGRANEX. F(3,30) = 1.014; P < 0.05; P = 0.416 
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• There was no significant difference for size (area in centimeter) with REGRANEX. 
F(3,30) = 0.211; P < 0.05; P = 0.887 
T bl 8 Th a e e mean an d d d d .. f h f h stan ar eVlatlOn 0 percent esc ar 0 eac treatment ~roup. 
Group INITIAL MONTH 1 MONTH 2 MONTH 3 
REGRANEX 12.5 ± 9.6 O±O 2±4.5 4±8.9 
Non-REGRANEX 66.7 ± 29.4 37.9 ± 32.6 10±14.1 O±O 
Table 9. The mean and standard deviation of size (area in centimeters) for each 
treatment group. 
Group INITIAL MONTH 1 MONTH 2 MONTH 3 
REGRANEX 3.7±5.0 3.0 ± 3.9 2.1±3.1 2.0±3.1 
Non-REGRANEX 2.8 ±4.0 0.9 ± 1.1 0.4 ± 0.5 0.2 ± 0.3 
When looking at Table 10, the number of wounds having 0% eschar increased for 
the REGRANEX group. 
Table 10. Total number of wounds with 0% eschar at each time interval 
Group INITIAL MONTH 1 MONTH 2 MONTH 3 
REGRANEX 1 4 4 4 
Non-REGRANEX 0 2 2 0 
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When looking at Table 11, the total number of healed wounds based on the area at 
Month 3 was 2 with REGRANEX and 1 with No REGRANEX. 
Table 11. Total number of healed wounds based on size (area in centimeters) at each 
time interval. 
Group INITIAL MONTH! MONTH 2 MONTH 3 
REGRANEX 0 0 1 2 




Depth measurements were not included in this study due to the fact that some of 
the measurements were either not taken or not recorded in the charts. It was felt that the 
missing information would not give accurate statistical data so therefore it was not 
include in this study. 
It was also felt that the subject with the ID number of 1 should not be included in 
the statistical analysis. This subject's ulcer was diagnosed as a venous stasis ulcer. Since 
REGRANEX is approved for lower extremity diabetic neuropathic ulcers, it was decided 
that only subjects who carried this diagnosis would be included in the study. 
The treatment groups were very different from the start. This makes it difficult to 
compare them. The mean of percent of eschar changed from 66.667% to 0% for the non-
REGRANEX group and 12.5% to 4% for the REGRANEX group. The mean size (area 
in centimeters) changed from 2.81 to 0.21 for the non-REGRANEX group and 3.67 to 
2.004 for the REGRANEX group. This indicates that the non-REGRANEX group had 
more eschar and the area was smaller than the REGRANEX group. It also shows that 
size of the wound changed more with the non-REGRANEX group then with the 
REGRANEX group. 
The statistical analysis appears to demonstrate that REGRANEX was not 
effective in this retrospective clinical trial. An interaction did occurred between 
treatment and time for percent eschar. However it was for the non-REGRANEX group 
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and it occurred between initial evaluation and Month 2. There was also a significant 
difference for percent eschar at initial evaluation and Month 1 between treatment groups 
but again these groups were very different from the start. 
Even though it was not shown to be very effective, the REGRANEX group has an 
overall decrease in eschar tissue and increase in granulation tissue when compared to the 
non-REGRANEX group when looking at Table 12 in Chapter IV. At initial evaluation 
the REGRANEX group had 1 patient with 0% eschar and at Month 1 there were 4 
patients with 0% eschar. This indicates that REGRANEX does increase granulation 
tissue. This is consistent with the literature. REGRANEX has been proven in previous 
studies to increase the formation of granulation tissue.(A,I,N) 
When looking at size (area in centimeters), there was no interaction that occurred 
between the time and treatment groups. No significant differences were found when 
looking at the main effects and simple main effects for either treatment group or time. 
Limitations 
There were several limiting factors to this study. Since this study was done in a 
small community, one limitation of this study was the insufficient number of subjects 
who received REGRANEX. Statistical analysis was done on 7 subjects with a total of 12 
ulcers. A larger group would have given more accurate statistical outcomes. A minimum 
of25 to 30 randomly selected charts should be used for increased accuracy. 
There were some limiting factors because this was a chart review. They included 
interrater reliability and validity, patient compliance and the treatment of non-
REGRANEX patients. Interrater reliability and validity was impossible to achieve due to 
the varied number of people who did the measuring and treating of the ulcers. Patient 
compliance was also a factor. There is no access to patients when doing a chart review so 
I was unable to check to see if patients were following their prescribed treatment. The 
treatment regimen for non-REGRANEX varied and this can affect healing. Another 
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limiting factor was that some data was missing from the charts. This limited the amount 
of statistical analysis that could be completed on this study. 
Possible Future Studies 
Since there is a difference in literature as to the effectiveness ofREGRANEX, it 
should be investigated further. Future studies could also focus on venous stasis ulcers 
and pressure ulcers to see how effective REGRANEX is in these cases. Currently there is 
no literature available on how effective REGRANEX may be in these areas. 
Conclusion 
Since Physical Therapists are involved in wound care, I feel it is important for 
them to have information on the products they may be using in the clinic. This way they 
can make their own personal decision about the product. This study gives them a 
background on what REGRANEX is and investigates how and if it works. This study 
demonstrated REGRANEX is associated with less eschar and therefore more granulation 
tissue when viewed by the clinician. However, this was found to be not significant with 
statistical analysis. REGRANEX does not increase the incidence of healing when 
compared with patients who have not received REGRANEX as a treatment. 
Improvement in the formation of granulation tissue is a plus for patients with diabetes 
because it may prevent them from enduring the pain or other side effects that go along 
with debridement. The use of growth factors is good in theory but further investigation is 
warranted further, with a larger group, as to whether or not it works in the clinic. 
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APPENDIX A 
APPLICATION TO CONDUCT RESEARCH 
AT ALTRU HEALTH SYSTEM FACILITIES 
Any researcJrer proposing to conduct researcJr using patients, staff, or records of Altr" Health System 
must obtain organizational approval as weU as IRB approvaL Complete thi& applicationform and 
submit it along with a brief summary of the study, including consent and instruments to: V"uginia 
Esslinger, MS, RN. Altru Health Research Center, P.O. Box 6002, Grand Forks, ND 58206-6002 
~Altru physician/staff member 
Department ~ 
Advisor Da\/f . "Qe .lIiI\A . M0. pr 
Relationship to Altru, if any __ J_' ______ --=,..---.,---,-
__ " Coursework __ Thesis __ Dissertation 20ther ~+ 
~Student 
__ Faculty College/Department'--__ --"" ____________ _ 
Relationship to Altru, ifany _____________ _ 
__ Other O~ruriution ___________________ _ 
Position'-__________________ _ 
Relationship to Altru, ifany _____________ _ 
Please answer the following questions: 
1. Describe the nature and e.xtent of involvement expected of Altru staffwith your project (include 
specific staff members by name and/or title, specific activities requested of them and an estimate of 
the amount of their time that would be required). 
See.. attachetL Ahru-s · 
2. Describe the nature of patient contact required by your project, if applicable (i.e. access to 
medical records, patient interviews, etc.) (over) 
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1. I have already spoken with Pat Guthmiller,RN about this project. Once this project is 
approved I will need to get the chart numbers of the patients from her. Medical records 
will then be involved to retrieve the charts for me. The remaining part of the study will 
involve getting information from patient's charts by myself. 
2. The extent of patient contact will be done through the access of their medical charts. 
3. All patient's charts will be given an anonymous code. These along with all the 
information from this study will be kept in a locked cabinet in Room 1531 of the 
University of North Dakota Physical Therapy Department for 3" years and will be 
destroyed after this time. 
4. I will require access to patient's medical records and the information will be taken 
from these charts. 
5. The only space required will be space to review charts. 
6: Start: 6/1/99 
Completion at Altru: 10/1/99 
Completion of project: 12/99 
· 7. None 
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_EXPEDITED REVIEW REQUESTED UNDER ITE"4_ (NUMBER[S]) OF HHS REGULATIONS 
-2LEXEMPT REVIEW REQUESTED UNDER ITEM...!1.- (NUMBER[S]) OF HHS REGULATIONS 
PRINCIPAL 
UNIVERSITY OF NORTH DAKOTA HUMAN SUBJECTS REVIEW FORM 
FOR NEW PROJECTS OR PROCEDURAL REVISIONS TO APPROVED 
PROJECTS INVOLVING HUMAN SUBJECTS 
INVESTIGATOR: Melissa Woodl Dave Reiling TELEPHONE: 795-9285 DATE: 5/10/99 
ADDRESS TO WHICH NOTICE OF APPROVAL SHOULD BE SENT: UND, Physical Therapy, Box 9037, G.F., ND 58202-9037 
PROPOSED 
SCHOOL/COLLEGE:_U::.N:.=;DIM:...:....:,:e:.::d.::::lc!!!ln::..e ______ DEPARTMENT: PhysIcal Therapy PROJECT DATES: 6/1/99 to 
5/1/00 
PROJECT TITLE: Evaluation of the effectiveness of Regranex (becaplermln) on treatment of wounds 
FUNDING AGENCIES (IF APPLICABLE): _________________________ _ 
TYPE OF PROJECT (Check ALL that iPPIy): 
DISSERTATION OR 
..lL NEW PROJECT CONTINUATION RENEWAL THESIS RESEARCH _X_ STUDENT RESEARCH PROJECT 
_ CHANGE IN PROCEDURE FOR A PREVIOUSLY APPROVED PROJECT 
DISSERTATIONITHESIS ADVISER, OR STUDENT ADVISER: Dave ReDIng, MS, PT 
INVOLVES NON-APPROVED INVOLVES A 
PROPOSED PROJECT: INVOLVES NEW DRUGS (IND) USE OF DRUG _X_COOPERATING INSTITU-
TION 
IF ANY OF YOUR SUBJECTS FALL IN ANY OF THE FOLLOWING CLASSIFICATIONS, PLEASE INDICATE THE CLASSIFICA· 
nONeS): 




MENTALLY DISABLED FETUSES MENTALLY RETARDED 
_ UND STUDENTS (> 18 YEARS) 
IF YOUR PROJECT INVOLVES ANY HUMAN TISSUE, BODY FLUIDS, PATHOLOGICAL SPECIMENS, DONATED ORGANS, 
FETAL MATERIAL, OR PLACENTAL MATERIALS, CHECK HERE __ _ 
IF YOUR PROJECT HAS BEEN\WILL BE SUBMITTED TO ANOTHER INSTITUTIONAL REVIEW BOARD(S),PLEASE LIST NAME OF 
BOARD(S): 
Status: . _ SubmItted; Date _ Approved; Date PendIng 
1. ABSTRACT: (LIMIT TO 200 WORDS OR LESS AND INCLUDE JUSTIFICATION OR NECESSITY FOR USING HUMAN SUBJECTS. 
The purpose of this case study Is to revIew the effects of Regranex (becaplermln). Regranex Gel has been used on lower 
extremIty dIabetic neuropathIc ulcers whIch extend Into the subcutaneous tissue or beyond and the blood supply has not been 
compromised. Regranex contaIns a human platelet-derived growth factor which promotes the proliferation of cells for healing. 
From prevIous studIes, Regranex has been shown to Increase healing. I am goIng to use patient medIcal records from Altru to 
analyze how effective Regranex has been In clInIcal use when compared wIth patients who have not received Regranex. SubJects: 
50 MedIcal Charts will be revIewed from Altru HospItal Systems. Methods: The charts revIewed will Include 25 subJects who 
have been treated wIth Regranex (becaplermln) and 25 subJects who have not received Regranex (becaplermln) for the 
treatment of wounds. 
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PLEASE NOTE: Only Information pertinent to your request to utilize human subjects In your pro· 
ject or activity should be Included on this form. Where appropriate attach sections from your proposal (If seeking outside 
funding). 
2. PROTOCOL: (Describe procedures to which humans will be subjected. Use additional pages If necessary.) 
SUBJECTS: 50 charts will be used from Ainu. 25 charts will Include subjects who have received Regranex (becaplermln) and 25 charts will 
Include subjects who have not received Regranex (becaplermln) and have similar medical backgrounds such as diabetes, peripheral neuropathy and 
any other conditions which would effect healing time of wounds. 
PROCEDURE: 
These charts will be randomly selected from Medical Records at Ainu. Information being recorded will be from evaluations and treatments 
which have already been completed by a health professional. Information will be taken from the Inldal evaluation, at I month, at 2 months and 3 
months. It will Include Pain Level, Length, Width and Depth of wound and treatment procedure. I will be wing the attached form. See appendix 
A page 6. 
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3. BENEFITS: (Describe the benefits to the Individual or society.) 
This swdy will help Inform HealthCare professionals about Regranex (becaplermln). The results will show how effective It has been In clinical use so 
that HealthCare professionals can make educated decisions as to when to use this product. 
4. RISKS: (Describe the risks to the subject and precautions that will be taken to minimize them. The concept of risk goes beyond physical risk 
and Includes risks to the subject's dignity and self·respect, as wen as psycho-logical, emotional or behavioral risk. If data are collected 
which could prove harmful or embarrassing to the subject If associated with him or her, then describe the methods to be used to Insure 
the confidentiality of data obtained, Including plans for final disposition or destruction, debriefing procedures, etc.) 
This Is a chart review and since treatments have already been completed, there are no physical risks to the patients. 
To ensure confidentiality, Information will be anonymously coded and Individuals will not be personally Identified In any 
publication. The Information collected wID be kept for 3 years In a locked cabinet In room 1531 of the University of 
North Dakota Physical Therapy Department and then It will be destroyed. 
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5. CONSENT FORM: A copy of the CONSENT FORM to be signed by the subject (If applicable) and/or any statement to be read to the 
subject should be attached to this form. If no CONSENT FORM Is to be used, document the procedures to be used to assure that Infringement 
upon the subject's rights will not occur. 
Describe where signed consent forms will be kept and for what period of dme. 
This Is a retrospective chart review and all padents may not be available for signed consent. All Informadon will be kept 
confldendal. Padents will be given a code to ensure this and names will not be used during the publlcadon of this 
Informadon. 
6. For FULL IRB REVIEW forward a signed original and thirteen (I 3) copies of this completed form, and where applicable, thirteen (13) copies 
of the proposed consent form, quesdonnalres, etc. and any suppordng documentation to: 
Office of Research 8: Program Development 
University of North Dakota 
Grand Forks, North Dakota 58202·7134 
On campus, mall to: Office of Research 8: Program Development, Box 7134, or drop It off at Room 105 Twamley HaD. 
For EXEMPT or EXPEDITED REVIEW forward a signed original and a copy of the consent form, quesdonnalres, etc. and any suppordng 
documentadon to one of the addresses above. . 
The policies and procedures on Use of Human Subjects of the University of North Dakota apply to all activities Involving use of Human Subjects 
performed by personnel conducting such actlvldes under the auspices of the University. No actlvldes are to be Initiated without prior review and 




fo;1ffl te 7 
Training or Center Grant Director Date 
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STUDENT RESEARCHERS: As of June 4, 1997 (based on the recommendation of UND Legal 
Counsel) the University of North Dakota IRB is unable to approve your project unless the following 
"Student Consent to Release of Educational Record" is signed and included with your "Human Subjects 
Review Form." 
STUDENT CONSENT TO RELEASE OF EDUCATIONAL RECORD
1 
Pursuant to the Family Educational Rights and Privacy Act of 1974, I hereby consent to the Institutional 
Review Board's access to those portions of my educational record which involve research that I wish to 
conduct under the Board's auspices. I understand that the Board may need to review my study data 
based on a q~estion from a parti~ipant or under a random audit. T~e study to which this release pertains 
Is Evaluatlon of the effectlVenessof Regranex (becaplenmn) on the treatment of wounds 
I understand that such information concerning my educational record will not be released except on the 
condition that the Institutional Review Board will not permit any other party to have access to such 
information without my written consent. I also understand that this policy will be explained to those 




Signature of Student Researcher 
t • 
Consent reqUIred by 20 U.S.c. 1232g. 
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MEMORANDUM 
To: Melissa WoodIDave ReIling 
University of North Dakota 
Physical Therapy Department 
Grand Forks. NO 58202 
From: Kevin I. Tveter. MD 
Chair 
Altru Health System IRE 
Date: June 11. 1999 
Re: Evaluation of the Effectiveness of Reg ran ex (bccaplennin) on Treatment of Wounds 
The above project was approved by me on June 10. 1999. and enclosed is a copy of the Research 
Project Action Report. Please complete the enclosed Research Project Completiontrennination 







P. O. Box 6003 
Gmnd Forks. NO 58206-6003 
Altru Clinic - Main Clinic 
1000 South Columbia Road _ P.O. Box 6003 _ Grand Forks. ND 58206-6003 _ 701-780-6000 
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ALTRU HEALTH SYSTEM 
APPROVAL TO CONouer RESEARCH STUDY 
AT ALTRU HEALTH SYSTEM 
Name: Melissa Wood Date: June 7, 1999 
Address: 750 N. 43ni Street. #47B, Grand Forks, ND 58203 
Telephone Numbers: Work. ________ Home 701-795-9285 
Department/College : Physical TheraID' Dept School of Medicine and Health Sciences, UND 
Project Title : Evaluation of the Effectiveness ofRegranex ffiecaplennin) on the Treatment of 
Wounds 
a 
Your request to conduct the above named study at an Altru Health System fucility involving 
employees or patients as participants, and/or requiring facility resources has been reviewed. The 
following action has been taken: 
L Permission to conduct the study is granted 
__ Permission to conduct the study will be granted upon completion of the 
following: 
__ Permission to conduct the study is denied for the following reason(s): 
SIgnature 
WOI'IfI=earch\prmsufrm 
~ ~ ~  ~a,N2Ja.­




.",.- Hhlilb SylmJ 
Institutional Review Board 
Research Project Action Report · 
Date: __ --"'J".,un"'-'e"-1.:.:0~ .....l1,:::9.:::;99~ _________ IRB #: ____ ~PT~-....:O::....I:....:I"--___________ _ 
Principal Investigator. Melissa WoodlDave Reiling Department: Physical Therapy Phone #: 795·9285 
Address to which notice of approval should be sent: UND. Physical Therapy. Box 9037. Grand Forks ND 58202·9037 
Research Coordinator. _________________________ Phone #: ___ _ 
Project Title:_-=E~va5!!l~ua5!!t~io~n~o!.!..f.l!th.!.l:ewE::!ff~e~ct:!!iv~e2!n.!.l:e:=:ss~of:....:R~e~g~ra!:!.ln.:..l:e:,Qx.l.(~be::.lca~p~le:.wrm.,!.!.!,!Jin!.L.) ,:::0u.n ..!.T.:.:re<.!:a!l!tm~en~t~o!.!..f..!.W~o!.!:!u~nd:!.:s~ _____ _ 
The above referenced project protocol and informed consent was reviewed by the Altru Health System Institutional Revie~ 
Board on and the following action was taken: . 
: ..... . 
Cl Project approved. Next Scheduled review is on --:'-::-_-:-:---::::----=:::-:-:-=:-:=-===':"":"": ___ --:'-:-_~ __ ~ 
If no date is ~]iven. then review will be required in 12 months. (See REMARKS SECTION for any special condition.) 
Cl Project approved. EXPEDITED REVIEW NO. _______________________ _ 
Next scheduled review is on, ____________________________ _ 
~ Project approved. EXEMPT CATEGORY NO.-:--::-::~:-:::-:-:':4::_::'_::_::"::::'":_:_:_---------------
No periodic review scheduled unless so stated in REMARKS SECTION. 
Cl Project approval deferred. (See REMARKS SECTION for further information.) 
Cl Project denied. (See REMARKS SECTION for further information.) 
Cl Amendment approved 
Cl Administrative change approved 
Cl Protocol revision approved 
Cl Revised consent form approved 
Cl Adverse event reviewed· Date of event. _________________________ _ 
Cl Other _________________________________ ----
REMARKS: 
Any changes in protocol, adverse occurrences or deaths in the course of the research project must be reported immediatel 
to the IRS chairperson or the IRB office (780-6161). 
Date. __ '_~_,o_'_,q._~ __ _ 
If the proposed project is to be part of a research activity funded by a federal agency, a special assurance statement or a 




DATA COLLECTION TOOL 
"Evaluation of the Effectiveness of REG RAN EX (becaplermin) Gel 0.01% on the 
Treatment of Wounds" 
ID# _____ _ 
Age _____ _ 
Sex ------
Medical Diagnosis: ________________________ _ 
Past Medical History: _______________________ _ 
Location ofwound(s) on body from Altru eval. form: ____________ _ 
Stage of wound (circle): I IT ITI IV 
Objective Information: 
Initial Evaluation 1 month 2 month 3 month 
PainLe'\e1 
Length (head to toe) 




Other % like 
SIOU2h. Eschar 
Treatment Procedure (Including cleansing and home program): 
1. Circle: Regranex No Regranex 
2. Dressing: ________________________ _ 
3. Cleansing: ________________________ _ 
4. Other: (ie: ROM, Elevation, OtherMedications) _________ _ 
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APPENDIXC 
Indicate location of skin 
breakdownlwound by letter. 
If more than 1 area, 




FRONT RIGHT LEFT BACK 




STAGES FOR PRESSURE ULCERS ONLY: (If ulcer is covered with eschar, do not stage until eschar is removed.) 
Stage 1: Nonblanchable 
erythema of intact skin. the 
heralding lesion of skin 
ulceration. In individuals with 
darker skin, discoloration of the 
skin, warmth, edema, 
induration or hardness may 
also be indicators. 
Stage II: Partial thickness skin 
loss involving epidermis, 
dermis or both. The ulcer is 
superficial and presents 
clinically as an abrasion, blister 
or shallow crater. 
Stage III: Full thickness skin 
loss involving damage to or 
necrosis 'of subcutaneous 
tissue that may extend down 
to, but not through, underlying 
fascia. The ulcer presents 
clinically as a deep crater with 
or withbut undermining of 
adjacent tissue. 
Stage IV: Full thickness skin 
loss with extensive destruction, 
tissue necrosis. or damage to 
muscle, bone or supporting 
structures (Le., tendon, joint 
capsule). Undermining and 
sinus tracts also may be 
associated with Stage IV 
pressure ulcers. 
Wound Etiology: Pressure Ulcer (Stage - see above): Leg Ulcer (Etiology: IF KNOWN): 
Surgical Wound (Surgical Procedure): Skin tear: other 
A. B. 
Size: cm (L) Size: cm (L) 
cm (W) cm (W) 
cm (0) cm (0) 
Oate: __________________ _ 
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C. O. 
Size: cm (L) Size: __ cm (L) 
cm (W) __ cm(W) 
cm (0) cm (0) 
Signature: _________________ _ 
Medical Park & Associates ' 
Initial Wound Documentation Record 
a!sd!!:u S01HlJ72·A JAN ga 
~ 
DATE/INITIALS 
LOCATION OF WOUND/KEY LETTER 
SKIN Length (head to toe) 
(Weekly) Width (side to side) 
*AII Depth (deepest portion) 
Measurements UnderminingfTunnel - location 
in em. (measure with applicator) 
Exposed Tendon: YorN 
Exposed Bone: Y or N 
COLOR 
% of Granulation "beefy" red 
% of Epithelial "pearly" pink 
% of Slough (yellow, gray or white) 
% of Eschar (thick, black) 
DRAINAGE 
Sanguinous Serous 
Sero-Sang Purulent - COLOR 
Describe type and amount of dressing saturated 
ODOR 
None, Mild, Foul (present after cleansing) 
PERI·WOUND SKIN CONDmON 
Intac! Red (Erythema) White 
Abrased Purple Gray 
Dry Macerated Edematous 
Widest Point of Induration 
Location of Induration (12, 3, 6, 9 o'clock) 
CLEANSING ROUTINE: 
TREATMENT (Describe type of dressing in detail) 
PATIENT'S PERCEPTION OF PAIN 
(Scale of 0 to 10) 0 = None 10 = Greatest 
Initials: Signature: Initials: Signature: 
Initials: Signature: Initials: Signature: 
CHome Home SeNicu . Wound Care Flowsheet CAItN Hospital 
CAItN Heann Inlli1lllt 
CAIIN Clinic 
~df!.ru 
6011~371-FS JUNE 98 
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